Journal of Stem Cell Research & Therapeutics最新文献

{"title":"Therapeutic use of opioids in the elderly patient","authors":"Maria Cecilia Ciaccio Vendola","doi":"10.15406/jsrt.2023.08.00160","DOIUrl":"https://doi.org/10.15406/jsrt.2023.08.00160","url":null,"abstract":"The continuous use of opioid drugs has its origin best known for analgesia since the discovery of its use as an anesthetic and its therapeutic use nowadays has become relatively high due to elderly patients, mainly with chronic pain of oncological and musculoskeletal origin. However, with the aging process, both drug doses and analgesic effects must undergo new adjustments to obtain the expected results. And, in addition to the concern about drug interactions and maintenance of periodic examinations in the elderly, there are greater risks involving tolerance and pseudo addiction, which may mix physical and psychological dependence. This work intends to elucidate the pharmacodynamics in aging and update dose adjustments and possible effects in the therapeutic use of opioids in the elderly.","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128473350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Other sea star Igkappa gene cloning assay in E. coli with new parameters","authors":"M. Leclerc","doi":"10.15406/jsrt.2023.08.00159","DOIUrl":"https://doi.org/10.15406/jsrt.2023.08.00159","url":null,"abstract":"The plasmid vector pET-28b(+) named “Young” was produced according a work of 2014.1 This construct is designed to allow the expression of a 13.6 kDA protein with a C-terminal 6histag. It is supposed to be an anti-HRP (Horse-radish peroxydase protein). This protein was not expressed in first E. coli: we attempt to explain this phenomenon.","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127564887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantum biology in regenerative medicine","authors":"P. Hollands","doi":"10.15406/jsrt.2023.08.00158","DOIUrl":"https://doi.org/10.15406/jsrt.2023.08.00158","url":null,"abstract":"This review explores the potential of Quantum Biology in the understanding of the activation of hVSEL stem cells using a QiLaserTM. There is a focus on the quantum mechanics of the interaction of modulated laser light from the QiLaserTM on the hVSEL stem cell surface antigen CXCR4-EPI-X4 complex. Understanding cell biology and the action of the QiLaserTM at the quantum level may allow significant advances in physiology, pathology and treatment.","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127773426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation induced therapeutic effects in cancerous and tumor cells: A review","authors":"R. Upadhyay, Priyan Rai","doi":"10.15406/jsrt.2023.08.00156","DOIUrl":"https://doi.org/10.15406/jsrt.2023.08.00156","url":null,"abstract":"Present review article describes use of radiation and radionuclides on cancer and cancer cell therapeutics. It also sketches out cumulative effects of radiation exposure received by the patients during cancer diagnostics. Though, in cancer therapeutics a selected and permissible dose is provided in several cycles to ablate the neoplastic cells and improve the condition of patient, but radiation harms surrounding cells and imparts negative effects on biology of cells. Ionizing radiation (IR) promotes cancer cell death through cytotoxicity. This article emphasizes both remedial effects and biological effects of radiation and radio-resistance in cells. It suggests safe use of radionucleides by encapsulating them in nanomaterials so as to use it alternate to chemotherapy to destroy various cancer types to enhance the survival of normal cells. This article explains effect of ionizing and non-ionizing radiation on cellular metabolism and genetics.","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122110378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem cell therapies for ischemic heart disease: clinical trial outcomes and futures","authors":"G. I. Gallicano, Nina Kishore, Gino DiNicola, A. Molotkova, Jessica Hsueh","doi":"10.15406/jsrt.2022.07.00154","DOIUrl":"https://doi.org/10.15406/jsrt.2022.07.00154","url":null,"abstract":"Ischemic heart disease carries high morbidity and mortality despite modern pharmaceutical treatment and revascularization procedures. Biologic stem cell therapy offers the potential to revolutionize clinical outcomes for ischemic heart disease by reducing scarring and improving cardiac function. Several small randomized clinical trials have been done utilizing various methodologies, different types of stem cells and doses, and measuring different clinical outcomes. The findings of these individual studies, as well as larger meta-analyses, have been inconsistent likely due to the significant heterogeneity within the methods used. In this review, we provide a more structured approach by comparing the recent studies by type of disease, stem cells, dose, delivery method, and outcome in an effort to draw attention to the similarities and differences in these studies and the need for a standardized approach in larger trials. We show that out of all the current stem cell therapies that have been tried, Adult stem cells, primarily mesenchymal stem cells are currently the most promising for post-myocardial infarction and heart failure while granulocyte colony-stimulating factor and bone marrow mononuclear treatment show efficacy in treating ischemic cardiomyopathy. Lastly, we discuss the potential future directions of stem cell therapy for clinical application in ischemic heart disease.","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128918839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-rich plasma (PRP) as an alternative to fetal bovine serum (FBS) in the culture of mesenchymal stem cells in cell therapy","authors":"Arnaldo R. Santos Jr, TM Sheguti","doi":"10.15406/jsrt.2022.07.00153","DOIUrl":"https://doi.org/10.15406/jsrt.2022.07.00153","url":null,"abstract":"Stem cells (SC) are defined by having proliferation and differentiation properties, with cellular self-renewal capacity, due to these characteristics they are widely studied in the cell therapy field. The Mesenchymal Stem Cells (MSCs) represent the most studied population of SC, due to their capacity to originate cardiomyocytes, skeletal muscle, neural precursors, among other cells. To culture MSCs in the laboratory, culture medium supplemented with fetal bovine serum (FBS) must be used. Despite its extensive use in protocols for cell expansion, FBS presents potential risks that cannot be neglected and are difficult to eliminate from serum. An alternative to the use of SFB is platelet-rich plasma (PRP), which contains high concentration of growth factors (GFs) assisting in cell proliferation in vitro. The main objective of the study is to analyze the feasibility of replacing FBS with PRP from umbilical cord blood to supplement the cell culture medium.","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123827509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transplant immunology I: mechanisms of rejection in solid organ transplants","authors":"Diego Morazán Fernández, Marvin Duran Delgado, Francisco Rodríguez Amador","doi":"10.15406/jsrt.2022.07.00152","DOIUrl":"https://doi.org/10.15406/jsrt.2022.07.00152","url":null,"abstract":"Non-identical transplants (allogeneic) have been a modern medicine milestone; however, the major pitfall for completed succeed is the recognition of foreign organ by the immune system. The myriad variations in sequence of the molecules of the major histocompatibility complex (MHC) or human leukocyte antigen (HLA) between individuals are the major cause of allograft rejection. Thus, the recognition by the B or T lymphocytes of the receptor occurs in the hypervariable regions of the HLA molecules that triggers to the graft 3 types of rejection: hyperacute, acute, and chronic. In addition, the rejection could be cause antibody-mediated (ABMR), T-cell-mediated (TCMR), or both, which depends on the main branch is cause of rejection. This review will explore the mechanisms mentioned above and give an introductory insight into transplant immunology; thus, preparer the reader to delve into further reviews in a Histocompatibility or Immunogenetics laboratory purpose.","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129614714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized therapy: the crucial role of the DPYD c.2194G>A (V732I) allele in the treatment of colorectal cancer patients candidates for therapy with fluoropyrimidines","authors":"Maddaloni V, P. N, Perfetti A, Macrì A, D. S, D. L, Genco L, R. S, Boenzi R","doi":"10.15406/jsrt.2022.07.00151","DOIUrl":"https://doi.org/10.15406/jsrt.2022.07.00151","url":null,"abstract":"5-Fluorouracil (5FU) is a chemotherapeutic agent belonging to the class of antimetabolite drugs, which exert a toxic action causing death of neoplastic cells. 5FU is mostly used as a standard treatment for colorectal cancer; the development of toxicity phenomena is related to the partial or complete deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD), limiting factor of the catabolism of fluoropyrimidines. Only 3-5% of 5-FU is converted to an active metabolite, while 85% of the drug is inactivated by DPD to 5-fluoro-dihydrouracil (5-FDHU). A reduced enzymatic activity of the DPD can be the cause for the presence of adverse drug reactions and toxicity in the patient, with multiorgan involvement, which can sometimes lead to death. The variants of the DPYD gene recommended by the AIOM (Associazione Italiana di Oncologia Medica)guidelines are: DPYD*2A (IVS14+1G>A, c.1905+1G>A); DPYD*13 (c.1679T>G); DPYD c.2846A>T, D949V; DPYD c.1236G>A (HapB3); DPYD c.2194G>A (V732I).Patients with complete DPD deficiency are at high risk of life-threatening or fatal toxicity and should not be treated with fluoropyrimidines, but this is a rare condition; while patients with partial deficiency should be treated with a reduced dose of the drug. Before starting treatment it’s crucial to determine the genetic profile of the patients candidates to therapy with fluoropyrimidines. In our cohort of the 370 samples analyzed by Real Time PCR, 294(~80%) are wild type for each variant screened. : DPYD c.2194G>A (V732I) alleleis significantly represented in the population examinated: considering the 15% reduction in drug administration imposed by this genotype, molecular profiling is essential before starting therapy with 5FU.In our study we also found a rare variant DPYD F632F rs17376848 c.1896 T> C in a patient, whose relevancefor therapeutic purposes is currently of uncertain significance.","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131111251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell biologist’s perspective: Frontiers in Development of PROTAC-HDAC degraders.","authors":"A. Sobko","doi":"10.31219/osf.io/vua9r","DOIUrl":"https://doi.org/10.31219/osf.io/vua9r","url":null,"abstract":"Structure of the article: HDACsClassificationEpigenetic regulatorsHDACs and Epigenetics of AgingNon-histone substrates of HDACsHistone modifying multiprotein complexesInsight from knockout studiesHDAC inhibitorsMolecular and cellular mechanisms of action of HDAC inhibitorsMolecular mechanism of actionCellular mechanism of actionPre-clinical and clinical use of HDAC inhibitors PROTACs and Molecular Glues: bi-valent and mono-valent degradersClass I HDAC degradersHDAC6 degradersPROTACs targeting NAD+-dependent histone deacetylasesNon-selective HDAC degradersHistone methyltransferase-specific PROTACsHDAC PROTACs: molecular mechanismsHDAC PROTACs: cellular mechanismsDesign and Development of PROTAC-mediated HDAC DegradationTesting HDAC degradersOpen key questions and perspectives in developing HDAC-degradersLiterature CitedAcknowledgments","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126537081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of different serums on culture and growth pattern on equine adipose derived mesenchymal stem cells (hrs-AT MSC)","authors":"Subodh Kumar Maiti, G. Wouters, D. Spitkovsky, J. Hescheler","doi":"10.15406/jsrt.2021.07.00150","DOIUrl":"https://doi.org/10.15406/jsrt.2021.07.00150","url":null,"abstract":"Equine multipotent mesenchymal stem cells (hrs-MSC) can be isolated from various tissues including adipose tissue (AT). We have analyzed the effect of different serum sources on hrs-AT-MSC cultured and assessed proliferation, morphology, viability and immunophenotype and plasticity. The hrs-AT-MSC was cultured separately with growth media containing three different serums: 20% FCS (Gibco), 20% horse serum (Sigma) and 20% allogenic horse serum (Belgium lab) in CO2 incubators. The hrs-AT-MSC growth and proliferation was better in cultural conditions where 20% FCS and 20% horse serum (Sigma) were used. Mesenchymal stem cell count was highest in the condition where horse serum (sigma) was used than both FCS and horse allogenic serum. The viability was more in where allogenic serum (Belgium lab) was used than both FCS (Gibco) and horse serum (Sigma). Like FCS (Gibco), horse serum (Sigma) and allogenic horse serum (Belgium lab) also showed promising /positive effects on equine adipose tissue derived mesenchymal stem cell (hrs-At-MSC) culture and proliferation. Horse serum was found as efficient as fetal calf serum in supporting proliferation and differentiation of equine mesenchymal stem cells in vitro. Further studies are needed to analyze these aspects of MSC in tissue regeneration. Stem cell biology has attracted tremendous interest recently. It is hoped that it will play a major role in the treatment of a number of incurable diseases via transplantation therapy. Several verities of stem cells have been isolated and identified in vivo and in vitro. Very broadly they comprise of two major classes: embryonic and adult mesenchymal stem cells.1 Mesenchymal stem cells (MSCs) because of their self replication, differentiate into various types of mature cells and tissues, and regeneration capabilities are regarded as an excellent source of cells for tissue engineering and for treatment of various incurable diseases and therapeutic uses in gene therapy, drug delivery, and reconstructive surgery.2,3 Recently, induced pluripotent stem cells (iPSC) and embryonic stem cells (ESCs) attracted researchers in organogenesis and cell-mediated therapy experiments, however, teratoma formation, ethical issues, and graft vs host rejection are the major limitations in development and therapeutic application of these cells.4 Due to these limitations, mesenchymal stem cells (MSCs) from adult tissues are now attractive material for and tissue engineering and cell-mediated therapy.5 Isolation of MSC derived from equine species has been reported in a number of different tissues, including bone marrow,6 peripheral blood,7 fat tissue8 and umbilical cord blood.9 Adipose tissue derived equine MSC (hrs-AT-MSC) exhibit the ability to differentiate into different types of cells and tissues in appropriate culture conditions using growth factors and specific hormones into osteoblast, chondroblat and adipocytes and a profound proliferative ability without hampering their own genetic fir","PeriodicalId":172569,"journal":{"name":"Journal of Stem Cell Research & Therapeutics","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127426813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}